glp-1 triple agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor Effects, working principles and target

Factors That Affect GLP-1 Fatigue Duration Several patient-specific and treatment-related factors influence both the likelihood and duration of fatigue associated with GLP-1 medications

Research article safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes

Golen T

[PubMed] [Google Scholar] 70

Study population We implemented two active comparator, new user cohorts.26 The first cohort was composed of patients who started and continued on either a GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide (except the 3 mg/0.5 mL formulation indicated for weight loss), lixisenatide, semaglutide) or a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) for the first time between 1 January 2007 (the year these medications entered the UK market) and 31 December 2020

Effect of continued weekly semaglutide vs withdrawal on weight loss maintenance